Plain-English translation of NCT07428499 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people who already completed an earlier trial of ADX-324, a new injectable medication designed to help prevent severe swelling attacks in people with hereditary angioedema (HAE). Researchers want to learn more about how safe and effective this treatment is when people keep taking it for a longer period of time, and how it affects quality of life.
Hereditary angioedema causes unpredictable, painful swelling that can be life-threatening. This medication works in a new way to prevent attacks before they start, and this study will help doctors understand whether people can safely use this treatment long-term.
You likely qualify if…
You likely don't qualify if…
You will continue receiving injections of the medication at one of two dose levels, similar to what you did in the earlier study. The research team will monitor your safety, measure how the medication works in your body, track any swelling attacks you experience, and ask you questions about how the treatment affects your daily life and wellbeing. You will have regular clinic visits and may have blood tests throughout the study.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
United States